BiotechTube
NantOmics

NantOmics

Culver City, United States· Est.
nantomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

NantOmics is a private, US-based leader in molecular diagnostic testing for oncology, founded in 2012 by Dr. Patrick Soon-Shiong. The company's core offering is a comprehensive, integrated panomic analysis service that sequences DNA and RNA and measures protein levels from a patient's tumor to identify actionable alterations and match them to targeted therapies. As part of the NantWorks ecosystem, it aims to transform cancer care by enabling precision medicine through deep molecular profiling and data-driven clinical decision support.

Oncology

Technology Platform

Integrated panomic analytical platform combining whole genome sequencing, RNA sequencing, and quantitative proteomics, supported by a proprietary knowledge database to identify actionable molecular alterations and match them to targeted therapies.

Funding History

2
Total raised:$150M
Series B$100M
Series A$50M

Opportunities

The growing adoption of precision oncology and the increasing number of targeted therapies create a large market for comprehensive molecular profiling.
Integration within the NantWorks ecosystem offers potential synergies in data sharing, drug development, and clinical trial matching.
The shift towards value-based care supports tools that aim to match patients with the most effective treatments, potentially improving outcomes and reducing costs.

Risk Factors

Intense competition from larger, well-established diagnostic companies and academic medical centers.
Challenges in proving clinical utility and securing consistent insurance reimbursement for a comprehensive, high-cost test.
Operational complexity and cost of delivering an integrated multi-omics service with a rapid turnaround time.

Competitive Landscape

NantOmics competes in the comprehensive cancer genomic profiling market against major players like Foundation Medicine (Roche), Caris Life Sciences, and Tempus. It differentiates by emphasizing the integration of quantitative proteomics with DNA/RNA sequencing, a 'panomic' approach not universally offered. Success depends on demonstrating that this added layer of data provides clinically actionable insights not available from genomic sequencing alone.

More companies in Diagnostics & Precision Medicine →More companies in United States →